文献速递衰弱、肌少症与跌倒多重用药

药剂师主导的STOPPFrail衰弱老年人处方精简研究

Pharmacist-Led Deprescribing Using STOPPFrail for Frail Older Adults in Nursing Homes.
PubMed 文献 · J Am Med Dir Assoc · 2024-06-28

结果显示处方药数、药物费用(初期)、抗胆碱能与镇静负荷及药物适宜性指数均显著改善,跌倒、急诊就诊、非计划住院、生活质量和死亡无显著差异。

要点

  • STOPPFrail指导的药剂师处方精简可减少衰弱养老院老人的潜在不适当用药。
  • 精简后药物费用初期下降,抗胆碱能与镇静负荷及药物适宜性指数显著改善并维持6个月。
  • 跌倒、急诊、非计划住院、生活质量无显著恶化。

核心结论

  • STOPPFrail指导、药剂师主导的养老院处方精简似可显著减少潜在不适当用药、初期药物费用及抗胆碱能与镇静负荷,且未对其他患者结局造成不良影响。
  • 建议更广泛地将药剂师整合进养老院,以优化衰弱老年人的用药和健康结局。

研究设计与样本

  • 由药剂师依据STOPPFrail制定处方精简建议并提交居民的全科医生,由全科医生决定是否实施。
  • 在基线、审查后及审查后6个月测量处方药数、药物费用、抗胆碱能认知负荷、药物负担指数、改良药物适宜性指数、生活质量、非计划住院、急诊就诊、跌倒和死亡。

主要发现

  • 94%的居民至少被处方1种潜在不适当用药,最常见的潜在不适当用药为无明确记录适应证的药物(29.6%)和维生素D(16.9%)。
  • 向全科医生提供的348条建议中,203条(58%)被接受、193条(55%)被实施。
  • 与基线相比,审查后及6个月时平均药物数分别为16.0±6.1、14.6±5.7(P<.001)、15.4±5.5(P<.001)。
  • 与基线相比,审查后及6个月时每例患者月均药物费用分别为€186.8±123.7、€172.7±119.0(P<.001)、€186.4±121.2(P=.95)。
  • 审查后平均药物负担指数、抗胆碱能认知负荷和改良药物适宜性指数分别显著下降9.7%、9.6%和3.7%(P<.001),6个月时仍显著(P<.001)。

关键数值与推荐

  • STOPPFrail为用于预期寿命有限的衰弱成人的处方筛查工具,由药剂师据此制定精简建议。
  • 潜在不适当用药中最常见为无明确记录适应证的药物(29.6%)和维生素D(16.9%)。
  • 建议接受率58%、实施率55%。
  • 药物数在审查后和6个月均较基线显著下降(P<.001);药物费用仅在审查后显著下降(P<.001),6个月时与基线无显著差异(P=.95)。
  • 药物负担指数、抗胆碱能认知负荷和改良药物适宜性指数在审查后分别下降9.7%、9.6%和3.7%(P<.001),6个月时仍显著(P<.001)。

临床怎么用

  • 在养老院衰弱老年人中,可由药剂师依据STOPPFrail系统筛查潜在不适当用药并向全科医生提出精简建议。
  • 处方精简后需在6个月内随访药物数、抗胆碱能与镇静负荷及药物适宜性,费用获益可能不持久。
  • 精简过程中应同步监测跌倒、急诊就诊、非计划住院、生活质量和死亡等结局。

局限性

  • 研究为前瞻性、非盲、非随机设计,未设对照组。
  • 全科医生对建议的接受率为58%、实施率为55%,部分建议未落地。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the impact of pharmacist-guided deprescribing using the STOPPFrail (Screening Tool of Older Persons' Prescriptions in Frail adults with a limited life expectancy) criteria in frail older nursing home residents. DESIGN: Prospective, unblinded, non-randomized, intervention study. SETTING AND PARTICIPANTS: Adults aged ≥65 years with advanced frailty resident in 6 independent nursing homes in Ireland. METHODS: STOPPFrail-based deprescribing recommendations were developed by a pharmacist and presented to residents' general practitioners (GPs), who decided to implement or not. Measured outcomes included number of prescribed medications, medication costs, anticholinergic cognitive burden (ACB), drug burden index (DBI), modified medication appropriateness index (MMAI), quality of life (QoL), non-elective hospitalizations, emergency department visits, falls, and mortality were measured at baseline, post review, and at 6 months post review. RESULTS: Ninety-nine residents were recruited. Most (94%) were prescribed ≥1 potentially inappropriate medication (PIM). The most frequent PIMs were medications without a clearly documented indication (29.6%) and vitamin D (16.9%). Of 348 recommendations provided to GPs, 203 (58%) were accepted and 193 (55%) were implemented. Relating to baseline, post review, and at 6 months: the mean ± standard deviation (SD) number of medications was 16.0 ± 6.1, 14.6 ± 5.7 (P < .001), and 15.4 ± 5.5 (P < .001). The monthly mean ± SD medication cost per patient was €186.8 ± 123.7, €172.7 ± 119.0 (P < .001), and €186.4 ± 121.2 (P = .95). There were significant post-review decreases in the mean DBI, ACB, and MMAI of 9.7%, 9.6%, and 3.7%, respectively (P < .001), which remained significant at 6 months (P < .001). There were no significant differences in falls, emergency department visits, non-elective hospitalizations, or QoL. CONCLUSIONS AND IMPLICATIONS: STOPPFrail-guided deprescribing led by a pharmacist in nursing homes appeared to significantly reduce PIMs, medication costs (initially), and anticholinergic and sedative burdens, without adversely affecting other patient outcomes. Greater consideration should therefore be given to the wider integration of pharmacists into nursing homes to optimize the medications and health outcomes of frail older adults.

来源:J Am Med Dir Assoc,查看原文。版权归原作者所有。

引用

  1. Hurley E, Dalton K, Byrne S, et al. Pharmacist-Led Deprescribing Using STOPPFrail for Frail Older Adults in Nursing Homes. J Am Med Dir Assoc. 2024. PMID: 38950585. doi:10.1016/j.jamda.2024.105122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。